N/A
N=101
Role of Pancreatic Triglyceride Content in Beta-cell Function
Obesity · Type 2 Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT00602953 ↗Enrolled (actual)
101
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No intervention planned. (Other)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- University of Texas Southwestern Medical Center
- Primary completion
- Aug 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pancreatic and Liver Fat |
1.87; 6.57; 3.61; 5.85; 0.96; 4.09 | — |
| PRIMARY Beta-cell Function; AIRg - Acute Insulin Response to Glucose |
197.55; 321.09; 519.33; 8.9 | — |
| PRIMARY Insulin Sensitivity (SI) |
5.48; 2.28; 2.29; 1.55 | — |
| PRIMARY Disposition Index (DI) |
1001.8; 739.84; 1031.26; 15.61 | — |
Summary
The study evaluates if fat accumulates in the pancreas in individuals at risk of developing obesity-related diabetes. It also evaluates if the amount of fat in the pancreas can predict the residual functional capacity of the pancreas (insulin secretion).
Eligibility Criteria
Inclusion Criteria
- adults without prior history of pancreatic disease (other than diabetes)
Exclusion Criteria
- use of unapproved medications
- contraindications to the MRI procedure
- contraindications to frequent blood draws
- pregnancy
- use of more than 2 alcoholic drinks/day
Data sourced from ClinicalTrials.gov (NCT00602953). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.